Companies to contribute to panel sessions at Pharma Integrates conference taking place on the 26 - 27 November at the Riverbank Park Plaza, London
Actavis, DSM Biologics and Dr. Reddy’s are the latest companies to contribute to a number of pertinent panel sessions at this year’s Pharma Integrates conference taking place on 26 – 27 November at the Riverbank Park Plaza, London, organised by Life Sciences Index.
From Actavis, Kim Kjornas, Senior Director Sales & Marketing Rx/Gx Europe, will be joining panellists from Generic Pharma, Teva Pharmaceuticals and IMS Health to address the \'Future of Generics\'. This session will question if there room for a pure generics player in this new world and what will the new success factors be?
Joining the debate on \'Biosimilars – Big Pharma and generics treading on each other’s toes\' is Dr Fritjof Linz, Vice President of R&D/PD at DSM Biologics. Alongside PricewaterhouseCoopers and AstraZeneca, this panel will discuss the key factors for success in a biosimilars world from the two industry perspectives.
Seen as one of the major threats within the pharmaceutical industry, \'Globalisation vs Market Entry Barriers\' will tackle the global trend to source materials and APIs in Asia, increasing pressure on prices and financial pressure on healthcare systems. Murali Dhar, Senior Director Operations & Strategic Planning, Proprietary Products at Dr. Reddy’s is the latest speaker to contribute to this panel session alongside Xellia Pharmaceuticals and Boehringer Ingelheim.
To attend Pharma Integrates 2013 please contact Miranda Zouheir on +44 20 8667 2117 or email@example.com.